278 related articles for article (PubMed ID: 35101045)
1. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
[TBL] [Abstract][Full Text] [Related]
2. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
3. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
4. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib in
Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
[TBL] [Abstract][Full Text] [Related]
9. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
Luo Y; Yao B; Huang P; Zhao Y; Chen J
Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Fan Y; Chen J; Zhou C; Wang H; Shu Y; Zhang J; Hua H; Huang DC; Zhou C
Lung Cancer; 2020 Sep; 147():209-213. PubMed ID: 32738416
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study.
Wang X; Wang J; Chu Y; Hao J
J Cancer Res Ther; 2023 Dec; 19(6):1663-1668. PubMed ID: 38156935
[TBL] [Abstract][Full Text] [Related]
14. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
Li L; Jiang L; Wang Y; Zhao Y; Zhang XJ; Wu G; Zhou X; Sun J; Bai J; Ren B; Tian K; Xu Z; Xiao HL; Zhou Q; Han R; Chen H; Wang H; Yang Z; Gao C; Cai S; He Y
Clin Cancer Res; 2019 Dec; 25(23):6967-6975. PubMed ID: 31413010
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.
Chen K; Xu Y; Huang Z; Yu X; Hong W; Li H; Xu X; Lu H; Xie F; Chen J; Xu Y; Fan Y
Cancer Med; 2023 Oct; 12(19):19460-19470. PubMed ID: 37723837
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
18. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
Yang Y; Yang G; Li W; Hao X; Zhang S; Ai X; Lei S; Xu H; Wang Y
Thorac Cancer; 2023 Nov; 14(33):3275-3281. PubMed ID: 37740599
[TBL] [Abstract][Full Text] [Related]
19. Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.
Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S
Exp Hematol Oncol; 2023 Jun; 12(1):53. PubMed ID: 37296463
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]